Oncolytic adenoviruses in gastrointestinal cancers

Raquel T. Yokoda, Bolni Nagalo, Mitesh J Borad

Research output: Contribution to journalReview article

Abstract

Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements have been attained in the treatment of patients with advanced disease, resulting in limited improvement in survival rates in these patients. Oncolytic adenoviruses are being developed to address gastrointestinal malignancies. Each platform has evolved to maximize tumor-cell killing potency while minimizing toxicities. Tumor-specific bioengineered adenoviruses using chimeric promoters, prodrug convertase enzymes, lethal genes, tumor suppressor genes, and pseudo-typed capsids can provide the innovations for eventual success of oncolytic virotherapy. This article will review the developments in adenoviral platforms in the context of specific gastrointestinal cancers. From the bench to the implementation of clinical trials, this review aims to highlight advances in the field from its early days to the current state of affairs as it pertains to the application of adenoviral oncolytic therapy to gastrointestinal cancers.

Original languageEnglish (US)
Article number33
JournalBiomedicines
Volume6
Issue number1
DOIs
StatePublished - Mar 1 2018

Fingerprint

Gastrointestinal Neoplasms
Adenoviridae
Tumors
Genes
Neoplasms
Prodrugs
Health care
Oncolytic Virotherapy
Toxicity
Lethal Genes
Innovation
Cells
Capsid
Economics
Tumor Suppressor Genes
Enzymes
Survival Rate
Clinical Trials
Delivery of Health Care
Therapeutics

Keywords

  • Adenovirus
  • Assessment of adeno-vector safety
  • Gastrointestinal cancers
  • Oncolytic therapy
  • Oncovirotherapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Oncolytic adenoviruses in gastrointestinal cancers. / Yokoda, Raquel T.; Nagalo, Bolni; Borad, Mitesh J.

In: Biomedicines, Vol. 6, No. 1, 33, 01.03.2018.

Research output: Contribution to journalReview article

@article{56ddb10326ff46c2b534132a7ef54234,
title = "Oncolytic adenoviruses in gastrointestinal cancers",
abstract = "Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements have been attained in the treatment of patients with advanced disease, resulting in limited improvement in survival rates in these patients. Oncolytic adenoviruses are being developed to address gastrointestinal malignancies. Each platform has evolved to maximize tumor-cell killing potency while minimizing toxicities. Tumor-specific bioengineered adenoviruses using chimeric promoters, prodrug convertase enzymes, lethal genes, tumor suppressor genes, and pseudo-typed capsids can provide the innovations for eventual success of oncolytic virotherapy. This article will review the developments in adenoviral platforms in the context of specific gastrointestinal cancers. From the bench to the implementation of clinical trials, this review aims to highlight advances in the field from its early days to the current state of affairs as it pertains to the application of adenoviral oncolytic therapy to gastrointestinal cancers.",
keywords = "Adenovirus, Assessment of adeno-vector safety, Gastrointestinal cancers, Oncolytic therapy, Oncovirotherapy",
author = "Yokoda, {Raquel T.} and Bolni Nagalo and Borad, {Mitesh J}",
year = "2018",
month = "3",
day = "1",
doi = "10.3390/biomedicines6010033",
language = "English (US)",
volume = "6",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Oncolytic adenoviruses in gastrointestinal cancers

AU - Yokoda, Raquel T.

AU - Nagalo, Bolni

AU - Borad, Mitesh J

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements have been attained in the treatment of patients with advanced disease, resulting in limited improvement in survival rates in these patients. Oncolytic adenoviruses are being developed to address gastrointestinal malignancies. Each platform has evolved to maximize tumor-cell killing potency while minimizing toxicities. Tumor-specific bioengineered adenoviruses using chimeric promoters, prodrug convertase enzymes, lethal genes, tumor suppressor genes, and pseudo-typed capsids can provide the innovations for eventual success of oncolytic virotherapy. This article will review the developments in adenoviral platforms in the context of specific gastrointestinal cancers. From the bench to the implementation of clinical trials, this review aims to highlight advances in the field from its early days to the current state of affairs as it pertains to the application of adenoviral oncolytic therapy to gastrointestinal cancers.

AB - Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements have been attained in the treatment of patients with advanced disease, resulting in limited improvement in survival rates in these patients. Oncolytic adenoviruses are being developed to address gastrointestinal malignancies. Each platform has evolved to maximize tumor-cell killing potency while minimizing toxicities. Tumor-specific bioengineered adenoviruses using chimeric promoters, prodrug convertase enzymes, lethal genes, tumor suppressor genes, and pseudo-typed capsids can provide the innovations for eventual success of oncolytic virotherapy. This article will review the developments in adenoviral platforms in the context of specific gastrointestinal cancers. From the bench to the implementation of clinical trials, this review aims to highlight advances in the field from its early days to the current state of affairs as it pertains to the application of adenoviral oncolytic therapy to gastrointestinal cancers.

KW - Adenovirus

KW - Assessment of adeno-vector safety

KW - Gastrointestinal cancers

KW - Oncolytic therapy

KW - Oncovirotherapy

UR - http://www.scopus.com/inward/record.url?scp=85063935945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063935945&partnerID=8YFLogxK

U2 - 10.3390/biomedicines6010033

DO - 10.3390/biomedicines6010033

M3 - Review article

AN - SCOPUS:85063935945

VL - 6

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 1

M1 - 33

ER -